Summit Therapeutics Stock Hits 52-Week Low on $500M Secondary Offering Plan
SMMT is trading near its 52-week low of $12.575 (0.0% above the low).
Summary
Summit Therapeutics announced plans for a $500 million secondary offering, which has sent its stock to a 52-week low. This capital raise, representing approximately 5% of the company's market cap, follows a 424B5 filing yesterday and a universal shelf registration on June 9th. While intended to fund R&D and working capital, the offering is highly dilutive and comes despite recent positive Phase III data for ivonescimab and significant insider stock purchases. The company reported a substantial net loss of $1.08 billion in 2025, highlighting its ongoing need for capital.
At the time of this announcement, SMMT was trading at $12.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $12.58 to $30.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.